Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451400 | 0.90 | CHRNB2 (0.37) | SIGMAR1TMEM97HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL6434802 | 0.87 | SIGMAR1 (0.35) | KDM1ASIGMAR1TMEM97ESR1ESR2 | |
| Trifluoroacetic Acid SCHEMBL6434348 | 0.75 | TYR (0.37) | KDM1ATYRESR1ESR2 | |
| Trifluoroacetic Acid SCHEMBL4071422 | 0.74 | HTR6 (0.43) | SIGMAR1HPGDKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL1018462 | 0.74 | HTR6 (0.43) | SIGMAR1HPGDKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL5618525 | 0.69 | HPGD (0.45) | HPGDKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL3963270 | 0.68 | HTR6 (0.43) | SIGMAR1OPRM1OPRD1KMT2A | |
| Trifluoroacetic Acid SCHEMBL29823097 | 0.67 | HPGD (0.40) | HPGDKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL7330887 | 0.67 | KMT2A (0.74) | SIGMAR1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL8315420 | 0.66 | QDPR (0.50) | TYRHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1165495-B1 | RESORCINOL DERIVATIVES | PFIZER (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | KDM1A 2409/4885SIGMAR1 3938/4885TMEM97 2855/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | KDM1A 2409/4885SIGMAR1 3938/4885TMEM97 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.